Table 2. Tumoural expression of BRCA1, TXR 1 and TSP1 mRNA and treatment efficacy.
|
PFS (months)
|
OS (months)
|
RR, N (%)
|
||||||
|---|---|---|---|---|---|---|---|---|
| Genes | No. of patients | Median (95% CI) | P-value a | Median (95% CI) | P-value a | CR+PR (%) | SD+PD(%) | P-value |
| BRCA1 low | 66 (50) | 3.0 (2.3–3.7) | 0.021 | 10.5 (6.2–14.8) | 0.4 | 20 | 80 | 0.028 |
| BRCA1 high | 65 (50) | 6.0 (3.5–8.5) | 11.2 (7.2–15.3) | 42 | 58 | |||
| TXR1 low | 66 (50) | 5.5 (2.1–8.9) | 0.029 | 19.1 (10.4–27.9) | 0.003 | 45 | 55 | 0.018 |
| TXR1 high | 65 (50) | 3.0 (1.8–4.0) | 10.0 (7.4–12.7) | 18 | 82 | |||
| TSP1 low | 66 (50) | 2.6 (2.0–3.3) | <0.001 | 8.4 (5.2–11.6) | <0.001 | 22 | 78 | 0.035 |
| TSP1 high | 65 (50) | 6.1 (4.4–7.7) | 25.1 (11.1–39.2) | 41 | 59 | |||
Abbreviations: BRCA1=breast cancer 1 gene; CR=complete response; RR=response rate; PR=partial response; PFS=progression-free survival; OS=overall survival; CI=confidence interval; SD=stable disease; PD=progressive disease; TSP1=thrombospondin 1; TXR1=taxol resistance gene 1.
a
Log-rank P-value.